Hidradénocarcinome du cuir chevelu : à propos d’un cas

Sbai, Ali; Ouabdelmoumene, Asmae; Naciri, Farid; Elhfid, Mohammed; Mezouar, Loubna

doi:10.11604/pamj.2014.17.102.3485

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As hidradenocarcinoma is an aggressive and extremely rare tumour, there is no consensus treatment to date [15]. The treatment of choice remains surgery based on wide excision with healthy margins [7,22,23]. The role of the sentinel node technique is widely debated in the literature [24].…”

Section: Discussionmentioning

confidence: 99%

Temporo-frontal and parotidial hidradenocarcinoma: A case report

Ndèye Fatou Kane Ba,

Kanta Ka,

El Hadji Aliou Baldé

et al. 2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Introduction: Hidradenocarcinoma is a very rare malignant tumor of the sweat glands. Diagnosis is based essentially on histological and immunohistochemical studies. Standard treatment is surgery combined with radiotherapy if there is a prognostic factor for local recurrence. We report a case treated in our department. Observation: A 24-year-old female patient with no specific pathological history consulted the Joliot Curie Institute of the Dantec Hospital for a forehead nodule that appeared in 2012 and was painless, evolving towards February 2021 into two right temporo-maxillary masses progressively increasing in volume. Examination revealed two tumors of stony consistency, with smooth, ulcerated surface, infiltrated center, raised borders, budding, not bleeding on contact, painless, the largest measuring approximately 16cm, located at the temporofrontal and right parotid level with extension to the right auricle associated with homolateral periorbital edema and right retroauricular and submental adenopathies, the largest measuring 3x2cm. Parotid skin biopsy revealed nodular tumour masses in the deep dermis, composed of a proliferation of medium- to large-sized epithelial cells, sometimes clear with central nuclei and numerous atypia and abnormal mitoses. Epidermoid differentiation can be seen in places. The stroma is fibrino-hyaline. The appearance was suggestive of a hidradenocarcinoma. The cervical CT scan revealed an inhomogeneous tissue process, strongly enhanced after well-limited contrast injection, in close contact with the right parotid gland. Similar homolateral parietofrontal lesions were noted, as well as a spiky homolateral frontoparietal appearance with cortical irregularity. The extension work-up was negative. Conclusion: Hidradenocarcinoma is a very rare malignant tumour with a high risk of locoregional and distant recurrence, mainly in lymph nodes. Its prognosis is poor.

show abstract

Section: Discussionmentioning

confidence: 99%

Temporo-frontal and parotidial hidradenocarcinoma: A case report

Ndèye Fatou Kane Ba,

Kanta Ka,

El Hadji Aliou Baldé

et al. 2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

show abstract

“…Surgery is the mainstay of treatment, consisting of wide local excision with negative margins. [ 13 , 36 , 37 ]. Classical carcinoma surgery may be used but two-step surgery may enhance the quality of the margin control and excellent control can be achieved by Mohs micrographic surgery [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

“…Adjuvant radiation therapy is necessary when surgery is impossible, either because the tumour is unresectable or when a second surgical step, theoretically mandatory in case of incomplete primary surgery, is impossible or results in major local defects [ 14 ]. Radiation therapy may be given in the presence of factors of local recurrence like positive resection margins, vascular emboli, perineural invasion or nerve-sheath involvement, depth of infiltration, dermal lymphatic invasion, highly anaplastic morphology [ 39 , 40 , 41 ] complete resection of large tumours for nodal sterilisation, recurrent tumours, and residual lymph nodes when further surgery is not possible [ 7 , 37 ]. When radiotherapy is used, high doses ranging from 50 Gy–70 Gy are recommended [ 14 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

Current management approach to hidradenocarcinoma: a comprehensive review of the literature

Soni

Bansal

Kaushal

et al. 2015

ecancer

109

View full text Add to dashboard Cite

Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials.

show abstract

Hidradénocarcinome du cuir chevelu : à propos d’un cas

Cited by 2 publications

References 12 publications

Temporo-frontal and parotidial hidradenocarcinoma: A case report

Temporo-frontal and parotidial hidradenocarcinoma: A case report

Current management approach to hidradenocarcinoma: a comprehensive review of the literature

Contact Info

Product

Resources

About